Abstract
Familial Mediterranean fever (FMF) is the most common monogenic periodic fever syndrome and characterized by recurrent episodes of fever, serositis, arthritis, dermal manifestations, and long-term renal complications. The MEFV gene was described in 1997 as the gene responsible for FMF and is inherited in autosomal recessive manner. It encodes mutated protein pyrin, an important player in the innate immune system and the component of inflammasome which leads to exaggerated inflammatory response through uncontrolled production of interleukin-1. The recent progress in molecular genetics and understanding of pathogenesis showed a more complicated picture of FMF inheritance, penetrance, and pathogenesis. The pathogenesis is not completely understood although the gene responsible for FMF has been identified. Whether the pyrin mutation effect in FMF is due to a loss of function or a gain of function is still controversial. The diagnosis is mainly clinical and the genetic testing is indicated to support it. Colchicine remains the mainstay of treatment of FMF since 1972. It decreases the attacks, improves quality of life, and prevents amyloidosis. The recent advances in genetic testing and molecular studies has led to the development of new therapies of interleukin-1 inhibitors; anakinra, canakinumab, and rilonacept.
Similar content being viewed by others
References
Sönmez HE, Batu ED, Özen S (2016) Familial Mediterranean fever: current perspectives. J Inflamm Res 9:13–20
Sarı İ, Birlik M, Kasifoğlu T (2014) Familial Mediterranean fever: an updated review. European Journal of Rheumatology 1(1):21–33
Kucuk A, Gezer IA, Ucar R et al (2014) Familial Mediterranean fever. Acta Med (Hradec Kralove) 57:97–104
Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287(25):1302
French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17(1):25–31
The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4):797–807
Ben-Chetrit E, Touitou I (2009) Familial Mediterranean fever in the world. Arthritis Rheum 61:1447–1453
Ozen S, Batu ED (2015) The myths we believed in familial Mediterranean fever: what have we learned in the past years? Semin Immunopathol 37(4):363–369
Sarrauste de Menthière C, Terrière S, Pugnère D, Ruiz M, Demaille J, Touitou I (2003) INFEVERS: the registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 31(1):282–285
Shinar Y, Obici L, Aksentijevich I et al (2012) Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis 71(10):1599–1605
Marek-Yagel D, Berkun Y, Padeh S, Abu A, Reznik-Wolf H, Livneh A, Pras M, Pras E (2009) Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum 60(6):1862–1866
Booty MG, Chae JJ, Masters SL et al (2009) Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 60(6):1851–1861
Lachmann HJ, Sengul B, Yavuzsen TU et al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45:746–750
Kalyoncu M, Acar BC, Cakar N et al (2006) Are carriers for MEFV mutations “healthy”? Clin Exp Rheumatol 24:S120–S122
Federici S, Calcagno G, Finetti M et al (2012) Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. Ann Rheum Dis 71:1961–1965
Ozturk C, Halicioglu O, Coker I et al (2012) Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from western Anatolia, Turkey. Clin Rheumatol 31:493–501
Marek-Yagel D, Bar-Joseph I, Pras E, Berkun Y (2009) Is E148Q a benign polymorphism or a disease-causing mutation? J Rheumatol 36:2372
Giancane G, Ter Haar NM, Wulffraat N et al (2015) Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis 74:635–641
De Torre-Minguela C, Mesa del Castillo P, Pelegrín P (2017) The NLRP3 and pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol 8:43
Campbell L, Raheem I, Malemud CJ, Askari AD (2016) The relationship between NALP3 and autoinflammatory syndromes. Int J Mol Sci 17(5):725
Abderrazak A, Syrovets T, Couchie D et al (2015) NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol 4:296–307
Bozkurt Y, Demir A, Erman B, Gül A (2015) Unified modeling of familial Mediterranean fever and cryopyrin associated periodic syndromes. Computational and Mathematical Methods in Medicine 2015:893507
Wang DQH, Bonfrate L, de Bari O, Wang TY, Portincasa P (2014) Familial Mediterranean fever: from pathogenesis to treatment. J Genet Syndr Gene Ther 5:248
Sohar E, Gafni J, Pras M et al (1976) Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med 43(2):227–253
Capron J, Grateau G, Steichen O (2013) Is recurrent aseptic meningitis a manifestation of familial Mediterranean fever? A systematic review. Clin Exp Rheumatol 31:127–132
Rigante D, Lopalco G, Tarantino G et al (2015) Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. Clin Rheumatol 34(9):1503–1511
Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809
Kasifoglu T, Bilge SY, Sari I et al (2014) Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology (Oxford) 53(4):741–745
Lidar M, Yaqubov M, Zaks N et al (2006) The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 33(6):1089–1092
Kees S, Langevitz P, Zemer D et al (1997) Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM 90:643–647
Lidar M, Kedem R, Mor A, Levartovsky D, Lan-gevitz P, Livneh A (2005) Arthritis as the sole episodic manifestation of familial Mediterranean fever. J Rheumatol 32:859–862
Lidar M, Doron A, Barzilai A et al (2013) Erysipelas-like erythema as the presenting feature of familial Mediterranean fever. J Eur Acad Dermatol Venereol 27(7):912–915
Livneh A, Madgar I, Langevitz P (1994) Recurrent episodes of acute scrotum with ischemic testicular necrosis in a patient with familial Mediterranean fever. J Urol 151(2):431–432
Kukuy O, Livneh A, Ben-David A et al (2013) Familial Mediterranean fever (FMF) with proteinuria: clinical features, histology, predictors, and prognosis in a cohort of 25 patients. J Rheumatol 40(12):2083–2087
Van ser Hilst JC, Simon A, Drenth JP (2005) Herediaty periodic fever and reactive amyloidosis. Clin Exp Med 5(3):87–98
Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885
Demirkaya E, Saglam C, Turker T et al (2016) Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: results from a multicenter international registry. J Rheumatol 43(1):154–160
Ozen S, Demirkaya E, Erer B et al (2016) EULAR recommendation for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651
Lidar M, Yonath H, Shechter N et al (2012) Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 12(1):72–76
Gül A (2016) Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. Best Pract Res Clin Rheumatol 30(2):296–303
Ozdogan H, Ugurlu S (2017) Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol 10:1–12
Ben-Zvi I, Kukuy O, Giat E et al (2017) Anakinra for colchicine resistant familial Mediterranean fever—a randomized, double blind, placebo-controlled trial. Arthritis Rheumatol 69(4):854–862
Özçakar ZB, Özdel S, Yılmaz S et al (2016) Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 35(2):441–446
Van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S (2016) Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics 10:75–80
Gül A, Ozdogan H, Erer B et al (2015) Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Research & Therapy 17(1):243
Brik R, Butbul-Aviel Y, Lubin S et al (2014) Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol 66(11):3241–3243
Hashkes PJ, Spalding SJ, Giannini EH et al (2012) Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 157(8):533–541
Hashkes PJ, Spalding SJ, Hajj-Ali R et al (2014) The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int 2014:854842
Piram M, Koné-Paut I, Lachmann HJ et al (2014) Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 73(12):2168–2173
Ozen S, Demirkaya E, Duzova A et al (2014) FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 73(5):897–901
Erer B, Demirkaya E, Ozen S et al (2016) What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review. Rheumatol Int 36(4):483–487
Stankovic K, Hentgen V, Fellahi S et al (2017) Concordance between CRP and SAA in familial Mediterraneanfever during attack-free period: a study of 218 patients. Clin Biochem 50(4–5):206–209
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
None.
Funding
None.
Rights and permissions
About this article
Cite this article
Alghamdi, M. Familial Mediterranean fever, review of the literature. Clin Rheumatol 36, 1707–1713 (2017). https://doi.org/10.1007/s10067-017-3715-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-017-3715-5